New York State Common Retirement Fund
RLMD icon

New York State Common Retirement Fund’s Relmada Therapeutics RLMD Stock Holding History

New York State Common Retirement Fund’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180K Buy
+26,000
New +$182K ﹤0.01% 2417
2023
Q3 		– Sell
-192
Closed -$472 – 3354
2023
Q2 		$472 Sell
192
-11,958
-98% -$33.1K ﹤0.01% 3366
2023
Q1 		$27.5K Sell
12,150
-209
-2% -$721 ﹤0.01% 3083
2022
Q4 		$43.1K Sell
12,359
-21,237
-63% -$187K ﹤0.01% 3111
2022
Q3 		$1.24M Buy
33,596
+13,415
+66% +$372K ﹤0.01% 1866
2022
Q2 		$383K Buy
20,181
+7,137
+55% +$156K ﹤0.01% 2480
2022
Q1 		$352K Hold
13,044
– – ﹤0.01% 2563
2021
Q4 		$294K Sell
13,044
-9
-0.1% -$200 ﹤0.01% 2721
2021
Q3 		$342K Buy
13,053
+39
+0.3% +$1.04K ﹤0.01% 2669
2021
Q2 		$417K Buy
13,014
+114
+0.9% +$3.96K ﹤0.01% 2699
2021
Q1 		$454K Hold
12,900
– – ﹤0.01% 2501
2020
Q4 		$414K Hold
12,900
– – ﹤0.01% 2437
2020
Q3 		$485K Hold
12,900
– – ﹤0.01% 2227
2020
Q2 		$577K Buy
+12,900
New +$545K ﹤0.01% 2135

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

New York State Common Retirement Fund's RLMD Position: Q2 2026 in Review

New York State Common Retirement Fund opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 26,000 shares worth $180K. The stake represents ﹤0.01% of the portfolio and ranks #2417 among its holdings. This is a return to the name: New York State Common Retirement Fund previously reported a position in RLMD as recently as Q2 2023.

New York State Common Retirement Fund first reported a position in RLMD in Q2 2020 and has held it in 14 quarters since. The position peaked at $1.24M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • New York State Common Retirement Fund held 26,000 shares of Relmada Therapeutics worth $180K as of Q2 2026.
  • Relmada Therapeutics was a new New York State Common Retirement Fund position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #2417 holding.
  • New York State Common Retirement Fund first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 14 quarters since.
  • New York State Common Retirement Fund's Relmada Therapeutics position peaked at $1.24M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.